Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 134

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 134
---
 NanoMab Technology Limited. Radiopharm completed the assignment of the DUNP19 assets to Lantheus Holdings, thus terminating
the Exclusive License Agreement, dated March 22, 2022, with The Regents of the University of California.

During the year ended June
30, 2025, the Company entered into a strategic development services contract with Lantheus to advance clinical development of innovative
radiopharmaceuticals in Australia. Under the contract, Radiopharm will lead the clinical development efforts in Australia while Lantheus
covers all the clinical development costs associated with the program.

Radiopharm will also receive
up to US$2 million as one-off milestone payments upon achieving key clinical development objectives. Each payment will be made after each
milestone is completed. As of June 30, 2025, no milestones had been met.

Under the Lantheus contract,
the Company has promised to deliver and manage the clinical development. This has been assessed as a single performance obligation as
it is a significant service of integrating the interrelated clinical trial activities into one combined output.

Master Service Agreement with AtomVie

In September 2024, we
entered into a Master Service Agreement with AtomVie, which specializes in the GMP manufacturing and supply of finished-dose
therapeutic radiopharmaceuticals. Under the terms of the agreement, AtomVie will perform services relating to the development and
manufacturing of Lu-BetaBart, a Lutetium-conjugated B7-H3 targeting radioantibody. The agreement supports the development of B7-H3
pursued by Radiopharm Ventures. AtomVie’s services include the development and validation of radiolabelling processes and
methods, GMP-manufacturing, chemical, radiochemical and biological research, animal studies logistics for global distribution, and
regulatory support with a high-standard quality management system for both investigation and commercial drug products. Radiopharm
will pay AtomVie for work performed pursuant to an agreed upon work schedule.

The Master Service Agreement
is effective until December 31, 2025, and will renew automatically in one-year terms until mutually terminated by the parties. In addition,
either party may terminate the agreement in the event of default by the other party.

D. Exchange Controls

Australia has largely abolished
exchange controls on investment transactions. The Australian dollar is freely convertible into U. S. dollars. In addition, there are currently
no specific rules or limitations regarding